Author Archives: Julian Upton
By Julian Upton | Published: April 22, 2014
What’s the opposite of Black Tuesday? White Tuesday? Bright Tuesday? Because Tuesday the stock market was buzzing following the news that Novartis is to acquire GSK’s cancer drugs business, while selling its vaccines division to GSK. With the speculation of a $100bn Pfizer bid for AstraZeneca and Valeant Pharmaceuticals added in, prices went soaring. As of […]
By Julian Upton | Published: April 17, 2014
GlaxoSmithKline’s legal wrangle concerning corrupt practices in Poland was one target of a pharma expose by the BBC’s flagship current affairs show Panorama this week.
By Julian Upton | Published: April 4, 2014
A report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.
By Julian Upton | Published: March 27, 2014
Europe’s biotech industry body, EuropaBio, has launched a report urging European governments to remain committed to biotech research, development and innovation (RDI) incentives, following release of the European Commission’s (EC) 2014 Innovation Scoreboard.
By Julian Upton | Published: March 19, 2014
Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions. Omar Ali, a UK formulary development pharmacist and consultant to NICE, speaking at eyeforpharma’s Barcelona 2014 conference on Wednesday, explained that the UK price watchdog will prioritize considerations of wider societal benefit and unmet need as it […]